(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
Authors
Keywords
-
Journal
Nutrients
Volume 11, Issue 2, Pages 412
Publisher
MDPI AG
Online
2019-02-18
DOI
10.3390/nu11020412
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of breast cancer cell types and their prognostic power in breast cancer patients
- (2018) Fan Wang et al. BMC GENOMICS
- The Biological Activities of Oleocanthal from a Molecular Perspective
- (2018) Kok-Lun Pang et al. Nutrients
- Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
- (2018) Jeroen Claus et al. eLife
- The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment
- (2017) Nehad M. Ayoub et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
- (2017) Andres Lopez-Albaitero et al. OncoImmunology
- The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance
- (2016) Katarzyna Miekus ONCOLOGY REPORTS
- The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
- (2016) Mohamed M. Mohyeldin et al. Oncotarget
- Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
- (2015) M. Giuliano et al. CLINICAL CANCER RESEARCH
- Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.
- (2015) Janghee Woo et al. Gastroenterology Report
- Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
- (2014) A. Furlan et al. CANCER RESEARCH
- Oleocanthal, a Phenolic Derived from Virgin Olive Oil: A Review of the Beneficial Effects on Inflammatory Disease
- (2014) Lisa Parkinson et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
- (2014) Simonetta M. Leto et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Olive Phenolics as c-Met Inhibitors: (-)-Oleocanthal Attenuates Cell Proliferation, Invasiveness, and Tumor Growth in Breast Cancer Models
- (2014) Mohamed R. Akl et al. PLoS One
- Treatment of HER2-positive breast cancer
- (2013) Maria Cristina Figueroa-Magalhães et al. BREAST
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
- (2012) M. S. N. Mohd Sharial et al. ANNALS OF ONCOLOGY
- Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer
- (2012) Ana M. Gonzalez-Angulo et al. CANCER
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification
- (2011) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
- (2011) L. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- HGF-independent potentiation of EGFR action by c-Met
- (2011) A M Dulak et al. ONCOGENE
- (−)-Oleocanthal as a c-Met Inhibitor for the Control of Metastatic Breast and Prostate Cancers
- (2011) Ahmed Elnagar et al. PLANTA MEDICA
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease
- (2010) Rena Callahan et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis
- (2010) Okkyung Rho et al. MOLECULAR CARCINOGENESIS
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression
- (2009) X. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
- (2009) M. G. Ponzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started